The interim results of a Phase 3 study of Covaxin, an Indian vaccine developed by Bharat Biotech and the Indian Council of Medical Research, were peer-reviewed and published in The Lancet journal on Friday. According to the study, two doses of the vaccine provide 77.8% protection against symptomatic Covid. The efficacy data was disclosed by Bharat Biotech in a statement in July, but the studies’ results were not published in a peer-reviewed publication.
According to the Lancet study, the vaccination produces a strong antibody response. There were no serious vaccine-related adverse events or deaths among the trial participants. The bulk of the side effects, such as headaches, weariness, fever, and injection site soreness, were minor and occurred within seven days following immunization.
Discussion about this post